Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death
Mathias Jachs(Medical University of Vienna), Mattias Mandorfer(Medical University of Vienna), Peter Quehenberger, Benedikt Simbrunner(Austrian Academy of Sciences), Lukas Hartl(Medical University of Vienna), Philipp Schwabl(Austrian Academy of Sciences), Bernhard Scheiner(Medical University of Vienna), Matthias Pinter(Medical University of Vienna), Rafael Paternostro(Medical University of Vienna), Ernst Eigenbauer(Medical University of Vienna), Thomas Reiberger(ERN GUARD-Heart), Albert Friedrich Stättermayer(Medical University of Vienna), Michael Trauner(Medical University of Vienna), David Bauer(Austrian Academy of Sciences)
Cited by 56
Related Papers
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
|Gastroenterology|2014|563
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
|Annual Review of Pathology Mechanisms of Disease|2018|561
Pathophysiological mechanisms of liver injury in COVID‐19
|Liver International|2020|399
Cancer and liver cirrhosis: implications on prognosis and management
|ESMO Open|2016|287